A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
Active, not recruiting · NCT04666740 · Registry updated 2026-02-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy | Homologous Recombination Deficiency (HRD); Metastatic Pancreatic Ductal Adenocarcinoma | Active, not recruiting | Phase 2 | 2026-02-18 | NCT04666740 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Memorial Sloan Kettering Cancer Center | 753 |
| Merck Sharp & Dohme LLC | 650 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge (All protocol activities) | New York | United States | 3 |
| Memorial Sloan Kettering Bergen (All Protocol Activities) | Montvale | United States | 82 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All Protocol Activities) | Commack | United States | 4 |
| Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown | United States | 92 |
| Memorial Sloan Kettering Nassau (All Protocol Activities) | Rockville Centre | United States | 27 |
| Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison | United States | 86 |